Literature DB >> 9249215

The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.

E M Jones1, C M McMullin, A J Hedges, A M Lovering, L O White, D S Reeves, A P MacGowan.   

Abstract

Serum concentrations of ciprofloxacin were reviewed in 22 patients given ciprofloxacin 400 mg intravenously 12 hourly for severe infection. No dosage modifications were made in patients with renal impairment. Patients who had either bowel or liver pathology in addition to renal failure had significantly higher serum concentrations than all other patients. Dosage reduction of ciprofloxacin in patients with severe sepsis and impaired renal function is not required unless they have co-existent intra-abdominal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249215     DOI: 10.1093/jac/40.1.121

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Mutant prevention concentration (MPC) of ciprofloxacin against Salmonella enterica of epidemic and poultry origin.

Authors:  Rafaela Ferrari; Marciane Magnani; Roberta Barreiros Souza; Maria Cristina Bronharo Tognim; Tereza Cristina Rocha Moreira Oliveira
Journal:  Curr Microbiol       Date:  2010-09-25       Impact factor: 2.188

2.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

Review 3.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.

Authors:  Douglas N Fish; Isaac Teitelbaum; Edward Abraham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.

Authors:  Y H Hwang; M S Kim; I B Song; J H Lim; B K Park; H I Yun
Journal:  Vet Res Commun       Date:  2008-12-16       Impact factor: 2.459

Review 8.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

9.  Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.

Authors:  Alan Abdulla; Omar Rogouti; Nicole G M Hunfeld; Henrik Endeman; Annemieke Dijkstra; Teun van Gelder; Anouk E Muller; Brenda C M de Winter; Birgit C P Koch
Journal:  Eur J Clin Pharmacol       Date:  2020-04-19       Impact factor: 2.953

10.  Highly Sensitive Detection of the Antibiotic Ciprofloxacin by Means of Fiber Enhanced Raman Spectroscopy.

Authors:  Sebastian Wolf; Timea Frosch; Juergen Popp; Mathias W Pletz; Torsten Frosch
Journal:  Molecules       Date:  2019-12-10       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.